Outset Medical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6901451079
USD
4.72
0.67 (16.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Outset Medical, Inc. stock-summary
stock-summary
Outset Medical, Inc.
Pharmaceuticals & Biotechnology
Outset Medical, Inc. is a medical technology company. The Company offers Tablo, a dialysis machine. Tablo offers acute and chronic dialysis. Tablo produces dialysate that’s customized to the patient’s prescription. Its touchscreen guidance and animated instructions enables to train new users. Tablo has integrated water purification and produces dialysis on demand. The other features of Tablo include integrated blood pressure cuff and automated saline bolus and tracking. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels and allows providers to a single platform from the hospital to the home. The three subtypes of hemodialysis that are used in the hospital are Intermittent Hemodialysis (IHD), Slow Low Efficiency Dialysis (SLED) and CRRT. IHD is used at the bedside or an inpatient dialysis unit outside of the ICU, while SLED and CRRT are used in the ICU.
Company Coordinates stock-summary
Company Details
3052 Orchard Drive , SAN JOSE CA : 95134
stock-summary
Tel: 1 971 5633083
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 48 Schemes (30.5%)

Foreign Institutions

Held by 87 Foreign Institutions (8.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. D. Keith Grossman
Chairman of the Board
Mr. Scott Bartos
Director
Mr. Karen Drexler
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 245 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.56

stock-summary
Return on Equity

-57.38%

stock-summary
Price to Book

1.59